Clinical Trial Update: Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of SU011248 with gefitinib (Iressa) in patients with advanced renal cell carcinoma has completed, with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)
• SU011248

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-03-31